Catalyst

Slingshot members are tracking this event:

Janssen's(JNJ) XARELTO (rivaroxaban) 10 mg Dose in Reducing the Risk of Recurrent Venous Thromboembolism (VTE) PDUFA expected October 28, 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
JNJ Community voting in process
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Xarelto, Rivaroxaban, Venous Thromboembolism